irinotecan hydrochloride liposome injection

DRUG8 trials

Conditions

Biliary Tract CarcinomaEwing SarcomaGastric CancerLocally Advanced Rectal CancerNeuroendocrine Carcinomas (NEC)Relapsed Small Cell Lung CancerSmall Cell Lung Cancer

Phase 1

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

RecruitingNCT06340204

Peking University People's HospitalEwing Sarcoma

Start: 2024-03-25End: 2026-12-25Target: 44Updated: 2024-04-03

Phase 2

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruitingNCT06430827

Ba YiBiliary Tract Carcinoma

Start: 2024-06-30End: 2025-12-31Target: 20Updated: 2024-05-28

Phase 3

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

RecruitingNCT06128837

Luye Pharma Group Ltd.Relapsed Small Cell Lung Cancer

Start: 2024-03-03End: 2028-10-31Target: 686Updated: 2024-03-15

Phase 4

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

RecruitingNCT06467786

Tang-Du HospitalSmall Cell Lung Cancer

Start: 2024-03-15End: 2028-09-15Target: 24Updated: 2024-06-21

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

Not yet recruitingNCT06499610

First Affiliated Hospital Xi'an Jiaotong UniversityGastric Cancer

Start: 2024-07-15End: 2027-10-15Target: 44Updated: 2024-07-12

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Not yet recruitingNCT07014540

Beijing GoBroad HospitalNeuroendocrine Carcinomas (NEC)

Start: 2025-06-20End: 2027-12-31Target: 45Updated: 2025-06-11

Unknown Phase

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Not yet recruitingNCT06463548

Yunpeng LiuBiliary Tract Carcinoma

Start: 2024-07-01End: 2026-12-31Target: 30Updated: 2024-06-18

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

RecruitingNCT06894797

Peking University Cancer Hospital & InstituteLocally Advanced Rectal Cancer

Start: 2025-04-01End: 2027-10-31Target: 68Updated: 2025-03-25

Related Papers

Liposomal irinotecan together with vincristine and temozolomide (NALIRI-VT) for patients with relapsed or refractory Ewing sarcoma: A two-cohort, phase 1a/1b study.

Journal of Clinical Oncology2025-05-28

Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer.

2024-09-033 citations